ImmunityBio/$IBRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImmunityBio
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Ticker
$IBRX
Sector
Primary listing
Employees
688
Headquarters
Website
ImmunityBio Metrics
BasicAdvanced
$7.6bn
-
-$0.89
0.07
-
Price and volume
Market cap
$7.6bn
Beta
0.07
52-week high
$12.43
52-week low
$1.95
Average daily volume
14m
Financial strength
Current ratio
6.666
Quick ratio
6.242
Long term debt to equity
-128.41
Total debt to equity
-129.395
Interest coverage (TTM)
-2.33%
Profitability
EBITDA (TTM)
-245.413
Gross margin (TTM)
99.34%
Net profit margin (TTM)
-606.15%
Operating margin (TTM)
-185.41%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-34.38%
Return on equity (TTM)
117.10%
Valuation
Price to revenue (TTM)
49.812
Price to book
-8.78
Price to tangible book (TTM)
-8.65
Price to free cash flow (TTM)
-23.462
Free cash flow yield (TTM)
-4.26%
Free cash flow per share (TTM)
-0.311
Growth
Revenue change (TTM)
351.53%
Earnings per share change (TTM)
53.67%
3-year revenue growth (CAGR)
521.94%
3-year earnings per share growth (CAGR)
-5.62%
What the Analysts think about ImmunityBio
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
ImmunityBio Financial Performance
Revenues and expenses
ImmunityBio Earnings Performance
Company profitability
ImmunityBio News
AllArticlesVideos
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
Business Wire·5 days ago
ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
Business Wire·2 weeks ago
IBRX DEADLINE ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX
Newsfile Corp·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs